To be more specific, the BRAF mutation was not related with a prognostic value in stage II tumors in the QUASAR adjuvant study [302], but it was associated with a decreased overall survival (but not recurrence-free survival) in stage II/III cancers in the PETACC-3 adjuvant trial [303]. Here, BRAF is linked to cancer.